Drugs & Aging最新文献

{"title":"Correction: Anticholinergic Exposure, Drug Dose and Postoperative Delirium: Comparison of Dose-Related and Non-Dose-Related Anticholinergic Burden Scores in a Retrospective Cohort Study of Older Orthopaedic and Trauma Surgery Patients.","authors":"Carolin Geßele, Constanze Rémi, Vera Smolka, Konstantinos Dimitriadis, Ute Amann, Thomas Saller, Dorothea Strobach","doi":"10.1007/s40266-024-01173-2","DOIUrl":"10.1007/s40266-024-01173-2","url":null,"abstract":"","PeriodicalId":11489,"journal":{"name":"Drugs & Aging","volume":" ","pages":"177-178"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11799103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142982653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Hyperkalemia Risk in Frail Older Patients Using RAAS Inhibitors.","authors":"Anna M J Heemels, Nadine P P M Gadiot, Angele P M Kerckhoffs, Namiko A Goto","doi":"10.1007/s40266-024-01171-4","DOIUrl":"10.1007/s40266-024-01171-4","url":null,"abstract":"<p><strong>Purpose: </strong>Renin-angiotensin-aldosterone system inhibitors (RAASi) are widely used in treatment of cardiovascular and renal disease. While effective, they pose a risk of hyperkalemia. In the general population, risk factors for hyperkalemia include chronic kidney disease, congestive heart failure, and use of medication affecting potassium balance. These risk factors are prevalent in frail older patients. Therefore, this study aims to explore the prevalence and risk factors for hyperkalemia associated with RAASi use in this vulnerable population.</p><p><strong>Patients and methods: </strong>This single-center, cross-sectional study included RAASi users aged ≥ 70 years who presented at the emergency department. Clinical Frailty Scale (CFS) according to Rockwood was calculated retrospectively from information in clinical files. All patients with CFS ≥ 5 were considered frail. Hyperkalemia was defined as serum potassium ≥ 5.5 mmol/L at time of presentation at the emergency department. Potential risk factors for hyperkalemia in older patients were identified using logistic regression models.</p><p><strong>Results: </strong>Of the 2023 participants, 86 (4.3%) were hyperkalemic, with no significant difference between frail and non-frail patients (4.7% versus 3.3%, p-value 0.157). Hyperkalemic patients were slightly younger than non-hyperkalemic patients (median age 83 versus 84 years, p-value 0.023), and females were slightly overrepresented in both groups (52.6% and 53.5%, p = 0.867). Risk factors associated with hyperkalemia in older RAASi users included younger age (odds ratio (OR) 0.95, 95% confidence intervals (CI) 0.92-0.99, p = 0.010), diabetes mellitus (OR 1.67, 95% CI 1.05-2.65, p = 0.030), moderate to severe kidney failure (OR 9.87, 95% CI 6.01-16.21, p < 0.001), and use of potassium-binding agents (OR 14.62, 95% CI 1.56-137.40, p = 0.019) and potassium-sparing diuretics (OR 2.66, 95% CI 1.57-4.50, p < 0.001).</p><p><strong>Conclusions: </strong>Contrary to expectations, this study found no association between frailty and hyperkalemia in older RAASi users visiting the emergency department. These results suggest that frail older patients without additional risk factors can be treated with RAASi when indicated, similar to the general population. The main risk factors for hyperkalemia in this population remain consistent with those in the general population, emphasizing the importance of monitoring kidney function and medication use.</p>","PeriodicalId":11489,"journal":{"name":"Drugs & Aging","volume":" ","pages":"135-142"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-Centric Approach for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease in Older People.","authors":"Kevin T Mueller, Alene A Saavedra, Lauren A O'Keeffe, Jeffrey A Sparks","doi":"10.1007/s40266-024-01175-0","DOIUrl":"10.1007/s40266-024-01175-0","url":null,"abstract":"<p><strong>Purpose of review: </strong>The purpose of this review is to outline considerations for treating older adults with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) as it relates to infection, comorbidities, cancer, and quality of life.</p><p><strong>Recent findings: </strong>The recent 2023 American College of Rheumatology/American College of Chest Physicians guideline conditionally recommended specific disease-modifying antirheumatic drugs (DMARDs), antifibrotics, and short-term glucocorticoids to treat RA-ILD. Since RA-ILD often affects older adults, we contextualize these pharmacologic options related to infection, gastrointestinal (GI) effects, cancer, cardiovascular disease, and quality of life. Nearly all DMARDs and glucocorticoids are immunosuppressive and increase infection risk. Rituximab, mycophenolate, cyclophosphamide, and glucocorticoids may have particularly high infection risk. Many therapies recommended for treating RA-ILD have potential GI side effects. Antifibrotics have a high rate of nausea and diarrhea. Janus kinase inhibitors may increase risk of cancer and cardiovascular disease in older people. In older individuals, decisions must weigh the risks and benefits of drug options while considering clinical and social factors such as polypharmacy, adherence, cost, convenience, and social support. Management of RA-ILD in older individuals is complex and should consider risks and benefits, while optimizing quality and quantity of life through a shared decision-making process.</p>","PeriodicalId":11489,"journal":{"name":"Drugs & Aging","volume":" ","pages":"81-94"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142969814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Opioid Prescriptions for Low Back Pain among Military-Connected Older Adults Across Multiple Care Systems.","authors":"Janiece L Taylor, Patricia K Carreño, Shannon Alsobrooks, Alexander G Velosky, Germaine F Herrera, Maxwell Amoako, Megan O'Connell, Ryan C Costantino, Krista B Highland","doi":"10.1007/s40266-024-01176-z","DOIUrl":"10.1007/s40266-024-01176-z","url":null,"abstract":"<p><strong>Background: </strong>Untreated low back pain (LBP) in older adults can lead to disability and development of chronicity. Due to the potential development of medical comorbidities and negative risks associated with pharmacological use, chronic LBP management for older adults requires a responsive approach.</p><p><strong>Methods: </strong>The objective of this study is to evaluate the probability of (1) opioid prescription receipt and (2) opioid-sedative coprescription, in a sample of military-service-connected patients enrolled in the Veterans Health Administration (VHA) or TRICARE, ages 30-85 years, receiving care in three systems: VHA, Military Health System (MHS), and nonfederal (civilian) healthcare facilities. Generalized linear models evaluated inequities across intersections of age, race and ethnicity, and care system.</p><p><strong>Results: </strong>Age was negatively associated with opioid-sedative coprescription receipt (p < 0.001) but was not significantly associated with opioid prescription receipt (p = 0.09). Across both models, Asian and Pacific Islander, Black, and Latine patients were less likely than white patients to receive either outcome (p < 0.001-0.002). Opioid-sedative coprescription probability decreased across age for Asian and Pacific Islander (p = 0.003) and Latine (p = 0.01) patients in the MHS but increased in white patients.</p><p><strong>Conclusions: </strong>It is imperative that clinicians and healthcare systems provide effective and sustainable treatment for LBP in older adults, including programming, that enhances shared decision-making and whole-health approach championed by the VHA.</p>","PeriodicalId":11489,"journal":{"name":"Drugs & Aging","volume":" ","pages":"143-153"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11799026/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142982615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How Should Clinicians Discuss Deprescribing with Caregivers of Older Adults Living with Dementia? A Qualitative Study.","authors":"Lauren M Fasth, Casey J Kelley, Cathleen Colón-Emeric, Ariel R Green, Carolyn T Thorpe, Meredith Gilliam, Jennifer L Lund, Laura C Hanson, Joshua D Niznik","doi":"10.1007/s40266-024-01179-w","DOIUrl":"10.1007/s40266-024-01179-w","url":null,"abstract":"<p><strong>Background: </strong>Preventive medications are potential targets for deprescribing in older adults with dementia as goals of care change from preventive to palliative. Yet, prescribers lack communication guidance to address deprescribing.</p><p><strong>Objective: </strong>Using bisphosphonates as a case example, we sought to characterize and compare communication preferences of prescribers and family/informal caregivers regarding deprescribing.</p><p><strong>Methods: </strong>We conducted 23 semi-structured interviews with prescribers (12) and caregivers (11) of older adults with Alzheimer's disease or related dementias (ADRD). Prescribers and caregivers were asked to provide their impressions of seven conversation starters for discussing deprescribing, focusing on a case example using bisphosphonates. These phrases focused on topics including life expectancy, treatment burden, adverse effects, and costs. We used a qualitative framework analysis to identify relevant themes as prescribers and caregivers discussed their general perceptions of the potential benefits and harms of bisphosphonates and experiences with deprescribing.</p><p><strong>Results: </strong>Among prescribers, there were ten physicians and two nurse practitioners; most (nine) female and white. Among caregivers, eight were female, seven were white, and five were Latino/a. For both prescribers and caregivers, preferred conversation starters initiated a risk versus benefit discussion, emphasizing medication adverse effects and patient-specific factors, such as functional status and indication for treatment. While prescribers emphasized discussing common medication adverse effects, caregivers noted the importance of knowing a medication's potential impact on ADRD. The least preferred conversation starter for deprescribing among both groups focused on the extra effort and cost of continuing bisphosphonates. Discordance between caregivers and prescribers were identified in several phrases; notably, caregivers disliked statements that introduced discussions of prognosis and life expectancy.</p><p><strong>Conclusions: </strong>Deprescribing conversations may be best perceived by caregivers when introduced with a discussion of a medication's adverse effects and potential impact on cognition. In addition, deprescribing conversations should be tailored to patient-specific factors, including functional status, goals of care, and the role of their caregiver in medical decision-making. Avoiding discussions of medication cost, pill burden, and life expectancy may help reassure the caregiver that deprescribing is a form of medication optimization and not a withdrawal of care.</p>","PeriodicalId":11489,"journal":{"name":"Drugs & Aging","volume":" ","pages":"155-164"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11848725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-Reported Outcomes in Geriatric Oncology-Balancing Quality of Life and Therapeutic Effectiveness Using Primary Breast Cancer as a Model.","authors":"James Francis, Mark Baxter, Dana Giza, Kwok-Leung Cheung, Ruth Parks","doi":"10.1007/s40266-024-01167-0","DOIUrl":"10.1007/s40266-024-01167-0","url":null,"abstract":"<p><p>Breast cancer remains the most prevalent cancer worldwide, necessitating advancements in its management. Surgery remains the recommended primary treatment although neoadjuvant or adjuvant treatments, such as chemotherapy, may also be indicated. However, such medications confer a risk of toxicity, often resulting in dose reductions and hospitalisations. This morbidity is particularly pertinent within older patients, for whom their experience of breast cancer is already faced through the lens of unique challenges often including comorbidity, socioeconomic decline and limited support networks. Quality of life (QoL) assessments acknowledge the impact of diagnosis and treatment on patients' psychological, emotional and physical well-being. Multiple tools exist (each with their own strengths and weaknesses) ranging from the more comprehensive [such as the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)] to the more broadly focused [including the General Functional Assessment of Cancer Therapy (FACT-G)]. However, while such tools have existed for some time, there remains a gap in clinical guidance as to their integration, particularly within older patient cohorts. This article seeks to address these complexities in breast cancer decision-making by exploring how QoL assessment can best be utilised inform efficacy-tolerability trade-offs, and subsequently facilitate optimal patient-centred care.</p>","PeriodicalId":11489,"journal":{"name":"Drugs & Aging","volume":" ","pages":"1-7"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osteoporosis in Older Men: Informing Patient Management and Improving Health-Related Outcomes.","authors":"Carmelinda Ruggiero, Carla Caffarelli, Valeria Calsolaro, Laura Tafaro, Francesca Riuzzi, Valentina Bubba, Nicola Napoli, Marika Ferracci, Patrizia Mecocci, Andrea Giusti, Giuseppe Rinonapoli","doi":"10.1007/s40266-024-01163-4","DOIUrl":"10.1007/s40266-024-01163-4","url":null,"abstract":"<p><p>Osteoporosis has been usually considered a female disease, generally causing more fracture risk and complications in adult and older women compared to older men. While vertebral fractures occur in a small proportion of men during middle age, men generally fracture about 10 years later than women, with significant increases in fracture risk after about age 75. Independent of age, men experiencing fragility fractures have a higher risk of life-threatening events compared to women, but the risk of secondary fragility fracture overlaps between men and women. Often, male osteoporosis recognizes the overlap between secondary causes and primary osteoporosis risk factors. Assessment through physical examination, history, and laboratory tests is recommended, with dual-energy X-ray absorptiometry of bone density being the preferred diagnostic test for osteoporosis in men. A treatment program should include awareness of diet and vitamin D status, fall risk reduction, and pharmaceutical therapy. Medications that are fracture-reducing in older women should also achieve fewer fractures in older men; however, there is a paucity of studies in men with the primary outcome of fracture risk reduction. Most older men with osteoporosis should be treated with oral or intravenous bisphosphonates, denosumab especially when on androgen deprivation therapy, and initial anabolic treatment should be considered for men at very high risk of fracture. This review summarizes the main features of osteoporosis and fragility fractures in men and reports findings from the available pharmacological and non-pharmacological studies conducted in men.</p>","PeriodicalId":11489,"journal":{"name":"Drugs & Aging","volume":" ","pages":"21-38"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Individualizing Antiretroviral Therapy in the Older Patient.","authors":"Jennifer F Hoy","doi":"10.1007/s40266-024-01168-z","DOIUrl":"10.1007/s40266-024-01168-z","url":null,"abstract":"<p><p>Owing to widespread availability of potent and tolerable antiretroviral therapy, life expectancy of people with human immunodeficiency virus (HIV) has significantly increased. Consequently, the population of people with HIV are ageing, with over 50% over the age of 50 years, and it is expected that 25% will be over the age of 65 years by 2030. People diagnosed with HIV at older age tend to have more advanced disease, and may already be experiencing comorbidities that will influence the choice of initial antiretroviral treatment. Despite the well described changes in pharmacokinetics associated with ageing, there are a paucity of pharmacokinetics studies of contemporary antiretroviral drugs to help guide treatment for HIV. Irrespective of this, integrase inhibitor-based regimens have been shown to have similar treatment outcomes in older and young adults and are the preferred regimens for initiation and switching therapy in older adults. Non-acquired immunodeficiency syndrome (AIDS) comorbidities are more common in people with HIV owing to chronic immune activation and inflammation even in the presence of virological suppression on antiretroviral treatment. Screening and risk assessment of comorbidities is crucial as the presence of geriatric syndrome, frailty or neurocognitive impairment may impact medication adherence. Simplification of complex regimens, both antiretroviral and comorbidity treatments, is recommended to improve adherence. Regular medication reviews under the guidance of an experienced HIV pharmacist are recommended to identify adverse drug-drug interactions and inappropriate prescribing of drugs with potential adverse effects, such as falls risk. Antiretroviral stewardship has been shown to improve patient outcomes and quality of life for ageing people with HIV.</p>","PeriodicalId":11489,"journal":{"name":"Drugs & Aging","volume":" ","pages":"9-20"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142821993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in Medication Complexity and Post-Hospitalization Outcomes in Older Adults Hospitalized for Heart Failure.","authors":"Aayush Visaria, William McDonald, John Mancini, Andrew P Ambrosy, Min Ji Kwak, Ashkan Hashemi, Mark S Lachs, Andrew R Zullo, Monika Safford, Emily B Levitan, Parag Goyal","doi":"10.1007/s40266-024-01166-1","DOIUrl":"10.1007/s40266-024-01166-1","url":null,"abstract":"<p><strong>Introduction: </strong>Medication regimen complexity may be an important risk factor for adverse outcomes in older adults with heart failure. However, increasing complexity is often necessary when prescribing guideline-directed medical therapy at the time of a heart failure hospitalization. We sought to determine whether increased medication regimen complexity following a heart failure hospitalization was associated with worse post-hospitalization outcomes.</p><p><strong>Methods: </strong>This retrospective cohort study included Reasons for Geographic and Racial Differences in Stroke (REGARDS) participants aged at least 65 years hospitalized for heart failure between 2003 and 2014. We calculated changes between hospital admission and discharge in medication count (Δcount) and in the validated Medication Regimen Complexity Index (ΔMRCI), which incorporates each medication's dosage formulation, frequency, timing, and special instructions. The primary outcome was a composite of 90-day all-cause readmission and all-cause mortality post-discharge. We calculated ΔMRCI and Δcount, identified their predictors, and examined their association with the primary outcome.</p><p><strong>Results: </strong>Among 725 patients hospitalized for heart failure, the mean (SD) age was 77 (7.2) years, 46% were female, and 35% were Black. At discharge, nearly 75% had an increase in their medication regimen complexity and 60% had an increase in their medication count. Patients with the highest ΔMRCI and Δcount were more likely to be female and Black. Predictors of the highest ΔMRCI included Charlson comorbidity index and not being discharged home; predictors of the highest Δcount included intensive care unit stay. Approximately 48% of patients experienced a 90-day readmission or death. Neither ΔMRCI (highest versus lowest tertile; HR 1.14, 95% CI 0.86, 1.50) nor Δcount (HR 0.97, 95% CI 0.73, 1.27) were associated with 90-day outcomes.</p><p><strong>Conclusion: </strong>Following a heart failure hospitalization, increased medication regimen complexity was common but was not associated with 90-day post-hospitalization outcomes. These are reassuring data, suggesting that it is reasonable for clinicians to focus on optimizing medication regimens for patients with heart failure even if it increases regimen complexity.</p>","PeriodicalId":11489,"journal":{"name":"Drugs & Aging","volume":" ","pages":"69-80"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12074541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influenza and Aging: Clinical Manifestations, Complications, and Treatment Approaches in Older Adults.","authors":"Christian I Rosero, Stefan Gravenstein, Elie A Saade","doi":"10.1007/s40266-024-01169-y","DOIUrl":"10.1007/s40266-024-01169-y","url":null,"abstract":"<p><p>Influenza, a highly contagious respiratory viral illness, poses significant global health risks, particularly affecting older and those with chronic health conditions. Influenza viruses, primarily types A and B, are responsible for seasonal human infections and exhibit a propensity for antigenic drift and shift, contributing to seasonal epidemics and pandemics. The severity of influenza varies, but severe cases often lead to pneumonia, acute respiratory distress syndrome, and multiorgan failure. Older adults, especially those over 65 years of age, face increased risks of immune senescence, chronic comorbidities, and decreased vaccine efficacy. Globally, influenza affects millions of people annually, with significant morbidity and mortality among older. Epidemiological patterns vary with climate, and risk factors include age, immunocompromised status, and preexisting chronic conditions. In older adults, influenza frequently results in hospitalization and death, which is exacerbated by immunosenescence and biological organ changes associated with aging. Clinical manifestations range from mild symptoms to severe complications such as viral pneumonia and multiorgan failure. Diagnosis often relies on antigen or molecular tests, with radiological examination aiding in severe cases. Treatment primarily involves antiviral agents, such as oseltamivir and peramivir, with the greatest benefit observed when initiated early. Management of severe cases may require hospitalization and supportive care, including addressing complications, such as secondary bacterial infections and cardiovascular events. This article highlights the need for improved vaccination strategies and novel treatments, including monoclonal antibodies and adoptive T cell therapies, to better manage severe influenza infections in vulnerable populations such as older.</p>","PeriodicalId":11489,"journal":{"name":"Drugs & Aging","volume":" ","pages":"39-55"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}